Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Posted: October 29, 2022 at 3:01 am

NEW YORK and LONDON, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari received a letter from Nasdaq Listing Qualifications indicating that Akari is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

Read the rest here:
Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Related Posts